United Kingdom

People: Bruker Corp (BRKR.OQ)

BRKR.OQ on NASDAQ Stock Exchange Global Select Market

16 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Laukien, Frank 

Dr. Frank H. Laukien, Ph.D., is Chairman of the Board, President, Chief Executive Officer of Bruker Corporation. Dr. Laukien has been our Chairman, President and Chief Executive Officer since February 1991 and is our largest stockholder. Dr. Laukien also serves as a director of various subsidiaries of Bruker, none of which are publicly-traded companies. Dr. Laukien served as a director of ALDA (Analytical, Life Science & Diagnostics Association), an industry association formerly known as Analytical & Life Sciences Systems Association, or ALSSA, for several terms in the past, and was ALSSA Chairman from 2002 to 2003. Dr. Laukien holds a Bachelor of Science degree in physics from the Massachusetts Institute of Technology ("MIT"), as well as a Ph.D. in chemical physics from Harvard University. Dr. Laukien was a member of the Dean's Advisory Committee of the MIT School of Science until 2014, and a Trustee of the Rivers School in Weston, Massachusetts until 2013. In May 2017, Dr. Laukien was elected a senator of acatech, the German National Academy of Science and Engineering. As our largest stockholder and based on his long history of leading the profitable growth at Bruker, Dr. Laukien brings to the Board the perspective of a significant stakeholder with an in-depth knowledge of all aspects of our operations. He also provides extensive executive experience in organizational management, strategic planning, finance, global business development and life science tools markets, as well as the scientific and technical background required for a deep understanding of our key technologies, markets and industry dynamics.

Basic Compensation

Total Annual Compensation, USD 730,675
Restricted Stock Award, USD 2,081,280
Long-Term Incentive Plans, USD --
All Other, USD 1,667,950
Fiscal Year Total, USD 4,479,900

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 62,274 635,818.00
Name Fiscal Year Total

Frank Laukien


Gerald Herman


Falko Busse


Burkhard Prause


Juergen Srega


Mark Munch

As Of  31 Dec 2018